Over the past several years, Swiss Jomed has been one of the few small European stent companies to grow into a major cardiovascular device company. Last year's successful IPO was testimony to the company's strong sales growth. But it was two deals the company did following soon after the IPO, the acquisitions of US-based MediDyne and EndoSonics, that will test whether Jomed is ready to break out of the pack and compete on a truly global scale with medical device giants such as Guidant and Medtronic.
by David Cassak
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
